Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 1, 1999, Pages 4-11

  Kenyon, Thomas A ^a,b,e   Mwasekaga, M J ^c   Huebner, R ^d   Rumisha, D ^c   Binkin, N ^a,b   Maganu, E ^c  

^a BOTUSA Project   (Botswana)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Department of HIV AIDS Prevention and Care   (Botswana)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e American Embassy Gaborone   (United States)

Author keywords

Africa, Botswana; Directly observed therapy; Drug resistance; Human immunodeficiency virus; Survey; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BOTSWANA; CHILD; EPIDEMIC; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFANT; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; BOTSWANA; CHILD; COMORBIDITY; DISEASE OUTBREAKS; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PREVALENCE; RIFAMPIN; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0033044995     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Raviglione M C, Snider D E, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
2. Nunn P, Felten M. Surveillance of resistance to antituberculosis drugs in developing countries. Tubercle Lung Dis 1994; 75: 163-167.
3. Sudre P, Ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992; 70: 149-159.
4. Carpels G, Fissette K, Limbana V, et al. Drug resistant tuberculosis in sub-Saharan Africa: an estimation of incidence and cost for the year 2000. Tubercle Lung Dis 1995; 76: 480-486.
5. Vareldzis B P, Grosset J, de Kantor I, et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tubercle Lung Dis 1994; 75: 1-7.
6. World Health Organization. WHO Tuberculosis Programme: framework for effective tuberculosis control. WHO/TB/ 94.179. Geneva, Switzerland; WHO 1994.
7. Botswana National Tuberculosis Program. 1995 Annual Report. Ministry of Health, Gaborone, Botswana.
8. Cantwell M, Binkin N. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Tubercle Lung Dis 1997; 3: 205-214.
9. Ministry of Health, Republic of Botswana. Evaluation of the Botswana National Tuberculosis Programme. March 21-31, 1994. Government Printing Office.
10. International Union Against Tuberculosis and Lung Disease. Technical Guide for Sputum Examination for Tuberculosis by Direct Microscopy. Bull Int Union Tuberc 1978; 53 (Suppl 2): 1-16.
11. Mitchison D A. Bacteriology of tuberculosis. Tropical Doctor 1974; 4: 147-153.
12. Tshukamura M, Tshukamura S. Differention of M. tuberculosis and M. bovis by p-nitrobenzoic acid susceptibility. Tubercle 1964; 45: 64-65.
13. Virtanen S. A study of nitrate reduction by mycobacteria. Acta Tuberc Scand 1960; 48 (Suppl): 1-119.
14. Wayne I. G, Doubek J R, Russell R L. Tests employing Tween 80 as substrate. Am Rev Respir Dis 1964; 90: 588-597.
15. Kubica G P, Rigdon A L. Preliminary investigation of rapidly growing acid fast bacilli. Am Rev Respir Dis 1961; 83: 737-740.
16. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
17. Dean A G, Dean J A, Coulombier D, et al. Epi Info, Version 6: a word processing, database, and statistics program for epidemiology on microcomputers. Centers for Disease Control and Prevention, Atlanta, GA, USA, 1994.
18. Cohen D L, Bustreo F, Raviglione M C. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin Infect Dis 1997; 24 (Suppl 1): S121-S130.
19. Pablos-Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338: 1641-1649.
20. 1998 Annual Economic Report. Ministry of Finance. Government of Botswana. Gaborone, Botswana.
21. Pape J W, Jean S S, Ho J L, Hafner A, Johnson W D Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-272.
22. Whalen C C, Johnson J L, Okwera A, et al. A trial of three regimens to prevent tuberculosis in adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 801-808.
23. Halsey N, Coberly J S, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-791.
24. Edlin B R, Tokars J I, Grieco M H, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the Acquired Immunodeficiency Syndrome. N Engl J Med 1992; 326: 1514-1521.
25. Frieden T R, Sterling T, Pablos-Mendez A, Kilburn J O, Cauthen G, Dooley S W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-532.
26. Aital J, Barrera L, Reniero A, et al. Hospital outbreak of multiple resistant tuberculosis in Rosario, Argentina. Conference on Global Lung Health and the 1996 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD). Paris, France, 2-5 October, 1996 (Abstract): 63.
27. Valway S E, Greifinger R B, Papania M, et al. Multidrug-resistant tuberculosis in the New York State prison system, 1990-1991. J Infect Dis 1994; 170: 151-156.
28. Kenyon T A, Ridzon R, Luskin-Hawk R, et al. Nosocomial outbreak of multidrug-resistant tuberculosis. Ann Intern Med 1997; 127: 32-36.
29. Nunn P, Mungai M, Nyamwaya J, et al. The effect of human immunodeficiency virus type 1 on the infectiousness of tuberculosis. Tubercle Lung Dis 1994; 75: 25-32.
30. Nielsen N J. Primary and secondary resistance of Mycobacterium tuberculosis in eastern Botswana. Tubercle 1979; 60: 239-243.
31. Glynn J R, Jenkins P A, Fine P E, et al. Patterns of initial and acquired antituberculous drug resistance in Karonga District, Malawi. Lancet 1995; 345: 907-910.
32. Karklina A, Zalesky R, Binkin N. Drug-resistant Mycobacterium tuberculosis. Conference on Global Lung Health and the 1996 Annual Meeting of the International Union Against Tuberculosis and Lung Disease, Paris, France, 2-5 October, 1996 (Abstract).
33. Cowie R L. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 1994; 150: 1460-1462.
34. Cowie R L. The mycobacteriology of pulmonary tuberculosis in South African gold miners. Tubercle 1990; 71: 39-42.
35. McKenna M T, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med 1995; 332: 1071-1076.
36. Barr R G, Menzies R. The effect of war on tuberculosis. Results of a tuberculin survey among displaced persons in El Salvador and a review of the literature. Tubercle Lung Dis 1994; 75: 251-259.
37. Kessler P J. Tuberculosis in refugees: a neglected dimension of the 'global epidemic of tuberculosis'. Trans Roy Soc Trop Med Hyg 1995; 89: 241-242.
38. Braun M M, Kilburn J O, Smithwick R W, et al. HIV infection and primary resistance to antituberculosis drugs in Abidjan, Cote d'Ivoire. AIDS 1992; 6: 1327-1330.
39. Githui W, Nunn P P, Juma E, et al. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. Tubercle Lung Dis 1992; 73: 203-209.
40. Small P M, Hopewell P C, Singh S P, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
41. Conover C S, Ridzon R, Valway S E, Schoenstadt L, McAuley J, Paul W. Outbreak of multidrug-resistant tuberculosis at a methadone maintenance center - Chicago, 1994-1995. 45th Annual Epidemic Intelligence Service (EIS) Conference. Atlanta, GA, 22-26 April, 1996. (Abstract)
42. Bradford W X, Martin J N, Reingold A L, Schecter F G, Hopewell P C, Small P M. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348: 928-931.
43. MacDonald D S. Notes on the socio-economic and cultural factors influencing the transmission of HIV in Botswana. Soc Sci Med 1996; 42: 1325-1333.
44. De Bruyn M. Women and AIDS in developing countries. Soc Sci Med 1992; 34: 249-262.
45. Greenberg A E, Thomas P A, Landesman S H, et al. The spectrum of HIV-related disease among outpatients in New York City. AIDS 1992; 8: 849-859.
46. Perlman D C, Salomon N, Perkins M P. Gender differences among TB patients in an HIV endemic area. HIV Infect Women Conference. New York City, February 22-24, 1996. P 68 (Abstract).
47. Van den Broek J, Borgdorff M W, Pakker N G, et al. HIV-1 infection as a risk factor for the development of tuberculosis: a case-control study in Tanzania. Int J Epidemiol 1993; 22: 1159-1165.
48. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
49. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City: turning the tide. N Engl J Med 1995; 333: 229-233.
50. Chaulk C P, Moore-Rice K, Rizzon R, Chaisson R E. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274: 945-951.
51. Hong Y P, Kim S J, Kwon D W, Chang S C, Lew W J, Han Y C. The sixth nationwide national tuberculosis prevalence survey in Korea, 1990. Tubercle Lung Dis 1993; 74: 323-331.
52. Zhang L X, Kan G Q. Tuberculosis control programme in Beijing. Tubercle Lung Dis 1992; 73: 162-166.
53. Gonzalez E, Armas L, Alonso A. Tuberculosis in the Republic of Cuba: its possible elimination. Tubercle Lung Dis 1994; 75: 188-194.